bevacizumab + capecitabine + oxaliplatin + vandetanib

This is a combination regimen consisting of four agents: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. It is used in various cancers, including metastatic colorectal cancer and others[3][4][5]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that interferes with DNA synthesis and inhibits tumor cell proliferation. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Vandetanib** is an oral small molecule tyrosine kinase inhibitor targeting multiple receptors including VEGF receptor, epidermal growth factor receptor (EGFR), and RET proto-oncogene. This combination would be considered an investigational or experimental regimen for cancer treatment. Each component has established use in oncology; however, this specific four-drug combination does not have regulatory approval as a fixed regimen but may be studied in clinical trials for synergistic effects against certain advanced or refractory cancers.